PAVmed, Inc. Aktie News

PAVmed Inc (NASDAQ: PAVM) shares more than quadrupled on Wednesday after the company's subsidiary – Lucid Diagnostics – secured a major contract from the US government.

NEW YORK, Jan. 21, 2026 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has been awarded a contract by the U.S. Department of Veterans Affairs (VA) for its EsoGuard® Esophageal DNA Test , expanding access to esophageal precanc...

Report includes nearly 12,000 patients who underwent Lucid's EsoGuard® Esophageal DNA Test on samples collected using its EsoCheck® Esophageal Cell Collection Device Real-world data confirm excellent technical performance, very rapid cell-collection times, and appropriate physician use, consistent with previously published studies NEW YORK , Dec. 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  ...

PAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks Transcript

Recognized as the leading company in its size category in program honoring the top workplaces across the diagnostics and precision-medicine sectors NEW YORK , Nov. 20, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has ...

PAVmed Inc. ( PAVM ) Q3 2025 Earnings Call November 13, 2025 8:30 AM EST Company Participants Matt Riley Lishan Aklog - Chairman & CEO Dennis McGrath - President & CFO Conference Call Participants Anthony Vendetti - Maxim Group LLC, Research Division Presentation Operator Good morning, and welcome to the PAVmed's Third Quarter 2025 Business Update Conference Call. [Operator Instructions] This c...

NEW YORK , Nov. 13, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, being held November 20, 2025 in New York City. Denni...

Veris Health launched commercial phase of strategic partnership and relaunched development of implantable physiological monitor PAVmed signed letter of intent (LOI) to license groundbreaking endoscopic esophageal imaging technology Conference call and webcast to be held today, November 13, at 8:30 AM EST NEW YORK , Nov. 13, 2025 /PRNewswire/ --  PAVmed Inc.  (NASDAQ: PAVM) ("PAVmed" or the "Com...